"Bubbly Billionaire throws party for his latest investment-PATHWAY GENOMICS

Anonymous

Guest
I can just see this Kavanaugh mortgaging his movie studio for Pathway Genomics. Nope, ain't going to happen.

http://nypost.com/2014/06/12/relativity-media-to-close-1b-pre-ipo-funding/
Movie producer Ryan Kavanaugh wanted to upend all the rules of Tinseltown when he established Relativity Media 10 years ago.
Now he wants to cure cancer.
The bubbly 39-year-old billionaire threw a benefit on Wednesday for his latest investment, Pathway Genomics, a company that on June 3 revealed a $300 BRCA test for breast cancer. The tests are usually $4,000.
At the benefit, held at Kavanaugh’s Santa Monica, Calif., airport hangar, Ke$ha performed and the movie mogul and former hedge-fund investor mingled with the likes of models Amber Valletta and Alessandra Ambrosio.
Whether it’s charity events, medical investments or models, Kavanaugh has become quite the master of cause marketing.
He’s invested tens of millions of dollars in the privately held San Diego biotech firm, one of many non-movie-business companies he’s been pouring his cash into.
Kavanaugh acquired a dog-food company, FreeHand, in 2013 with singer and friend, Michael Bublé, to go along with stakes in Vapor Corp., an e-cigarette firm, a digital ad firm that greets airport travelers in their native languages with duty-free offers and Shoutz, a firm developing the global lottery business into the mobile era.
Whether in his personal portfolio or at Relativity, diversification is the name of the game for Kavanaugh.
Before and after the Pathway fundraiser, Kavanaugh has been hypnotizing East Coast hedge funds and private-equity firms with plans to take his studio public, Hollywood financing sources said.
The studio is working with Jefferies to close a $1 billion pre-IPO placement early next week, sources told The Post.
The placement calls for investors to see a public float of between 20 percent and 30 percent of the company within 12 months.
The IPO will value the firm at between $6 billion and $10 billion, sources tell The Post.
Kavanaugh, reached Thursday by The Post, declined comment.
Though there is no pure publicly held Hollywood entity that lines up like Relativity, LionsGate is a similar beast.
But the obsession of Kavanaugh and others inside Relativity is to diversify the studio enough so that its shares don’t swing wildly on every movie release’s success or disappointment.
Currently, 60 percent of Relativity Media’s revenue comes from theatrical releases, sources said.
But selling that mix to Wall Street investors — with its volatile nature — is no easy task.
So Kavanaugh is out to diversify his studio, sources told The Post.
By this time next year, sources familiar with the company said, the movie/non-movie revenue mix will move from 60/40 to closer to 50/50.
One plan to diversify includes a Relativity over-the-top platform — called RelaTV — where it would air its own original movies, TV shows and digital video, The Post has learned.
While the studio recently sold rights to its content to Netflix, that deal is non-exclusive.
Relativity has also pushed hard into other non-movie sectors, like:
• Relativity TV, which makes reality shows for Food Network, OWN and GSN.
• MadVine, a new unit aimed at bringing advertiser dollars direct to its projects.
• Relativity Digital, which creates digital video vignettes.
• Relativity Sports that has relationships with a host of athletes, including NBA stars Dwight Howard and Amar’e Stoudemire, according to the firm’s Web site.
• Relativity Music, which releases soundtracks from the company’s movies.
Movies carrying Ryan Kavanaugh’s producer credit have averaged $47.6 million per release, according to Boxoffice-mojo.com.
Those set to benefit from the IPO are Relativity Media’s current backers, including Ron Burkle’s Yucaipa Cos. and Kavanaugh’s original partner, Paul Singer’s Elliott Management.
Other lesser-known investors include: Jim Breyer, the CEO of Breyer Capital; Colbeck Capital; Softbank; Falcon Investments and China’s biggest bank, ICBC.
Relativity’s IPO won’t be the only one for investors to consider in the coming year.
MGM Studios, which creates the James Bond movies, is expected to go public after filing regulatory documents.
And there is also talk of WME/Silver Lake taking a merged WME and IMG Worldwide public in the years to come.
For Kavanaugh, however, Relativity will be just one of a number of chips on the poker table — but it will be his most important.
 






PATHWAY GENOMICS PRODUCT UNAPPROVED AND INEFFECTIVE


WASHINGTON – House Speaker John Boehner invited James Plante, the CEO of Pathway Genomics, to attend President Obama's jobs speech Thursday as an example of a business leader whose efforts to create jobs have been stymied by "excessive regulations."

House Republicans, including Sen. Boehner, held a forum to discuss job creation in March. The CEO of Pathway Genomics took part.

However, reports by the independent Government Accountability Office (GAO) and the Food and Drug Administration indicate the product Boehner, R-Ohio, claimed was unfairly maligned by federal regulators was unapproved and ineffective.

Pathway created home genetics tests for consumers to see whether they were at risk for 70 medical conditions. Pathway teamed with Walgreens to sell the kit in May 2010, but after the FDA wrote Pathway to say the agency had no record of its seeking approval for the device, Walgreens pulled out.

STORY: Obama unveils $447B jobs package


Boehner's news release presents the case differently: "Despite being in compliance with all available FDA regulations, the FDA attacked Pathway in the media following the announcement of the partnership. (Walgreens) consequently backed out, and Pathway was unable to create those 100 new high-paying jobs."

Reports from the FDA, GAO and the medical community show there's no proof the tests actually work.

Jeffrey Shuren, director of the FDA's Center for Devices and Radiological Health, told a House committee in July 2010 that he had seen faulty data analysis, exaggerated clinical claims, fraudulent data and unacceptable clinical performance associated with the tests.

"These tests have not been proven safe, effective or accurate," Shuren said.

Michael Watson, director of the American College of Medical Genetics, agreed. "I think the general feeling was that we know too little about these tests to put them on the market," Watson told USA TODAY.

A July 2010 GAO report showed the tests are often unreliable. GAO investigators sent samples from the same people to four companies, the report said. In one case, the companies told the same donor he was at below-average, average and above-average risk for the same diseases.

San Diego-based Pathway Genomics, its website says, no longer sells tests directly to consumers over the Internet. It provides reports only to physicians.

House Republicans handled questions for Plante.

Dan Conston, a spokesman for Rep. Peter Roskam, R-Ill., said Pathway was chosen because it and the others "exemplify businesses and sectors hurt by excessive Washington-imposed barriers preventing them from innovating, growing and creating more jobs."
 
























Hey potty mouth Manager;

What do you think of your big blabber mouth now? Still gonna defend this cheap sleezy company and your potty mouth?
Ms. Grammar police aka potty mouth manager, is it grammatically correct to use words like moron, dirtbag, losers, etc.,?

If I were you, that disgusting video with the dancers in their underwear should be pulled.
You do nothing for the image of Pathway Genomics, any person thinking of joining Pathway Genomics that has half a brain, reads your comments would you want to work for sleezeballs like this?

Yuk, embarrassing and so very unprofessional the whole lot of them.
 






It is actually Billionaire Kavanaugh than owns Relativity Media which did the promotion of the launch of BRCATrue- READ here:

Angela Courtin has been wooed away from Dentsu Aegis Network by Relativity Media, where she will serve as the company's first chief marketing officer.

Courtin is charged with running the company's marketing initiatives for its film, television and sports divisions as well as leading all branding and advertising campaigns. She'll also oversee Madvine, Relativity's branded entertainment and consumer products arm as well as Relativity Digital. Courtin reports to CEO Ryan Kavanaugh and president Tucker Tooley.

"Angela understands the brand world more than anyone I know," said Kavanaugh. "We're the only studio that makes all of our own content and we have recognized that we could offer a brand direct access to our television and films with integrated storylines ... Angela is key to that process."

Madvine works with brands like Mondelez, Evian and Pathway Genomics, among others.

"We have a unique opportunity to leverage each division's compelling, engaging content to reach global audiences in entirely new ways while also empowering brands to tell their stories like never before," said Courtin in a statement about her new role.

Courtin recently stepped down as president of The Story Lab, Dentsu Aegis' Network's branded content agency that she founded, to focus on her role as president of Dentsu Aegis in the U.S. Before that she served as chief content officer for Aegis Media. Prior to that, Courtin held positions at MTV, MySpace and HBO.

A spokeswoman for Dentsu Aegis Network declined to comment or offer details on who will replace Courtin.
 












I can just see this Kavanaugh mortgaging his movie studio for Pathway Genomics. Nope, ain't going to happen.

http://nypost.com/2014/06/12/relativity-media-to-close-1b-pre-ipo-funding/
Movie producer Ryan Kavanaugh wanted to upend all the rules of Tinseltown when he established Relativity Media 10 years ago.
Now he wants to cure cancer.
The bubbly 39-year-old billionaire threw a benefit on Wednesday for his latest investment, Pathway Genomics, a company that on June 3 revealed a $300 BRCA test for breast cancer. The tests are usually $4,000.
At the benefit, held at Kavanaugh’s Santa Monica, Calif., airport hangar, Ke$ha performed and the movie mogul and former hedge-fund investor mingled with the likes of models Amber Valletta and Alessandra Ambrosio.
Whether it’s charity events, medical investments or models, Kavanaugh has become quite the master of cause marketing.
He’s invested tens of millions of dollars in the privately held San Diego biotech firm, one of many non-movie-business companies he’s been pouring his cash into.
Kavanaugh acquired a dog-food company, FreeHand, in 2013 with singer and friend, Michael Bublé, to go along with stakes in Vapor Corp., an e-cigarette firm, a digital ad firm that greets airport travelers in their native languages with duty-free offers and Shoutz, a firm developing the global lottery business into the mobile era.
Whether in his personal portfolio or at Relativity, diversification is the name of the game for Kavanaugh.
Before and after the Pathway fundraiser, Kavanaugh has been hypnotizing East Coast hedge funds and private-equity firms with plans to take his studio public, Hollywood financing sources said.
The studio is working with Jefferies to close a $1 billion pre-IPO placement early next week, sources told The Post.
The placement calls for investors to see a public float of between 20 percent and 30 percent of the company within 12 months.
The IPO will value the firm at between $6 billion and $10 billion, sources tell The Post.
Kavanaugh, reached Thursday by The Post, declined comment.
Though there is no pure publicly held Hollywood entity that lines up like Relativity, LionsGate is a similar beast.
But the obsession of Kavanaugh and others inside Relativity is to diversify the studio enough so that its shares don’t swing wildly on every movie release’s success or disappointment.
Currently, 60 percent of Relativity Media’s revenue comes from theatrical releases, sources said.
But selling that mix to Wall Street investors — with its volatile nature — is no easy task.
So Kavanaugh is out to diversify his studio, sources told The Post.
By this time next year, sources familiar with the company said, the movie/non-movie revenue mix will move from 60/40 to closer to 50/50.
One plan to diversify includes a Relativity over-the-top platform — called RelaTV — where it would air its own original movies, TV shows and digital video, The Post has learned.
While the studio recently sold rights to its content to Netflix, that deal is non-exclusive.
Relativity has also pushed hard into other non-movie sectors, like:
• Relativity TV, which makes reality shows for Food Network, OWN and GSN.
• MadVine, a new unit aimed at bringing advertiser dollars direct to its projects.
• Relativity Digital, which creates digital video vignettes.
• Relativity Sports that has relationships with a host of athletes, including NBA stars Dwight Howard and Amar’e Stoudemire, according to the firm’s Web site.
• Relativity Music, which releases soundtracks from the company’s movies.
Movies carrying Ryan Kavanaugh’s producer credit have averaged $47.6 million per release, according to Boxoffice-mojo.com.
Those set to benefit from the IPO are Relativity Media’s current backers, including Ron Burkle’s Yucaipa Cos. and Kavanaugh’s original partner, Paul Singer’s Elliott Management.
Other lesser-known investors include: Jim Breyer, the CEO of Breyer Capital; Colbeck Capital; Softbank; Falcon Investments and China’s biggest bank, ICBC.
Relativity’s IPO won’t be the only one for investors to consider in the coming year.
MGM Studios, which creates the James Bond movies, is expected to go public after filing regulatory documents.
And there is also talk of WME/Silver Lake taking a merged WME and IMG Worldwide public in the years to come.
For Kavanaugh, however, Relativity will be just one of a number of chips on the poker table — but it will be his most important.

look I just secured a position with Pathway in May, I am happy to know we have a sugar daddy in our corner. Maybe it will keep our positions secure in the next 12 months.
 












we reduce cancer? oops I must be incorrect with how I am selling the DNA test.

yes "sugar daddy" kavanaugh is a billionaire and invested in pathway genomics and owns the media promotion company that promoted the "pathway to the cure" celeb studded party with keesha dancing with her raunchy backup dancers.

need any more information, just let me know. kavanaugh = "sugar daddy"